The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|August 26, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-09-02-2015
- Volume 11
- Issue 9
WuXi PharmaTech Supplies Laboratory Testing Services to Lee's Pharm
Author(s)Pharmaceutical Technology Editors
WuXi's Laboratory Testing Division will be the exclusive supplier of laboratory testing services for Hong Kong-based Lee's Pharm.
Advertisement
WuXi PharmaTech and Lee's Pharm, a research-based biopharmaceutical company headquartered in Hong Kong with operations in China, announced on Aug. 26, 2015 that the two companies have signed an agreement whereby WuXi's Laboratory Testing Division (LTD) will be the exclusive supplier of laboratory testing services for Lee's Pharm. These services will include LTD's entire portfolio of discovery and investigational new drug/new drug application package services, including chemistry analytical services, in-vitro and in-vivo biology, oncology, immunology, in-vitro ADME (absorption, distribution, metabolism, and excretion) studies, pharmacokinetic/pharmacodynamic studies, toxicology, and clinical bioanalysis. LTD will provide dedicated program management, streamline project coordination across WuXi, and allocate the necessary resources and R&D development efforts for Lee's Pharm programs.
"WuXi's impressive platform of lab testing services will allow our compounds to advance seamlessly through discovery, preclinical, and clinical development," Benjamin Li, executive director and CEO of Lee's Pharm, said in a press release.
Source:
Articles in this issue
about 11 years ago
Technology Allows Automated Lab Reactor Controlabout 11 years ago
Flow Chemistry Systems Offer Optionsabout 11 years ago
Spectrometers Comply with FDA Electronic Signature Regulationabout 11 years ago
Pressure Reactor for Small Batch Reaction Chemistryabout 11 years ago
Homogenizer Offers Continuous Operationabout 11 years ago
Mayne Pharma to Invest $65m in Manufacturing Expansionabout 11 years ago
Next Step for Elemental Impuritiesabout 11 years ago
Cytovance Biologics Acquired by Hepalinkabout 11 years ago
Industry Responds to FDA Metrics ProgramAdvertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Advertisement
Advertisement